Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Details on high frequency blood collection, data analysis, available material and patient characteristics in BIOMArCS.

Boersma E, Vroegindewey MM, van den Berg VJ, Asselbergs FW, van der Harst P, Kietselaer B, Lenderink T, Oude Ophuis AJ, Umans VAWM, de Winter RJ, Oemrawsingh RM, Akkerhuis KM.

Data Brief. 2019 Nov 5;27:104750. doi: 10.1016/j.dib.2019.104750. eCollection 2019 Dec.

2.

Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission.

Vroegindewey MM, van den Berg VJ, Bouwens E, Akkerhuis KM, Oemrawsingh RM, Asselbergs FW, Lenderink T, van der Harst P, Ronner E, Umans VAWM, Kardys I, Boersma E.

Am Heart J. 2019 Oct;216:143-146. doi: 10.1016/j.ahj.2019.02.016. Epub 2019 Apr 6.

PMID:
31053235
3.

Temporal Pattern of Growth Differentiation Factor-15 Protein After Acute Coronary Syndrome (From the BIOMArCS Study).

Buljubasic N, Vroegindewey MM, Oemrawsingh RM, Asselbergs FW, Cramer E, Liem A, van der Harst P, Maas A, Ronner E, Schotborgh C, Wardeh AJ, Akkerhuis KM, Boersma E; BIOMArCS investigators.

Am J Cardiol. 2019 Jul 1;124(1):8-13. doi: 10.1016/j.amjcard.2019.03.049. Epub 2019 Apr 18.

PMID:
31047655
4.

High-Frequency Biomarker Measurements of Troponin, NT-proBNP, and C-Reactive Protein for Prediction of New Coronary Events After Acute Coronary Syndrome.

Oemrawsingh RM, Akkerhuis KM, de Mulder M, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Liem A, Haitsma D, van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Ilmer B, Dijkgraaf R, de Winter RJ, Kie The SH, Wardeh AJ, Hermans W, Cramer E, van Schaik RH, Hoefer IE, Doevendans PA, Simoons ML, Boersma E; BIOMArCS Investigators.

Circulation. 2019 Jan 2;139(1):134-136. doi: 10.1161/CIRCULATIONAHA.118.036349. No abstract available.

PMID:
30592652
5.

The temporal pattern of immune and inflammatory proteins prior to a recurrent coronary event in post-acute coronary syndrome patients.

Vroegindewey MM, Oemrawsingh RM, Kardys I, Asselbergs FW, van der Harst P, Oude Ophuis AJ, Etienne Cramer G, Maas A, Hong Kie The S, Wardeh AJ, Mouthaan H, Boersma E, Akkerhuis KM.

Biomarkers. 2019 Mar;24(2):199-205. doi: 10.1080/1354750X.2018.1539768. Epub 2018 Dec 4.

PMID:
30514120
6.

Prognostic Value of Intravascular Ultrasound in Patients With Coronary Artery Disease.

Schuurman AS, Vroegindewey MM, Kardys I, Oemrawsingh RM, Garcia-Garcia HM, van Geuns RJ, Regar E, Van Mieghem NM, Ligthart J, Serruys PW, Boersma E, Akkerhuis KM.

J Am Coll Cardiol. 2018 Oct 23;72(17):2003-2011. doi: 10.1016/j.jacc.2018.08.2140.

7.

Associations of 26 Circulating Inflammatory and Renal Biomarkers with Near-Infrared Spectroscopy and Long-term Cardiovascular Outcome in Patients Undergoing Coronary Angiography (ATHEROREMO-NIRS Substudy).

Anroedh SS, Akkerhuis KM, Oemrawsingh RM, Garcia-Garcia HM, Brankovic M, Regar E, van Geuns RJ, Serruys PW, Daemen J, van Mieghem NM, Boersma E, Kardys I.

Curr Atheroscler Rep. 2018 Sep 14;20(10):52. doi: 10.1007/s11883-018-0752-8. Review.

8.

Appropriate use criteria for optical coherence tomography guidance in percutaneous coronary interventions : Recommendations of the working group of interventional cardiology of the Netherlands Society of Cardiology.

IJsselmuiden AJJ, Zwaan EM, Oemrawsingh RM, Bom MJ, Dankers FJWM, de Boer MJ, Camaro C, van Geuns RJM, Daemen J, van der Heijden DJ, Jukema JW, Kraaijeveld AO, Meuwissen M, Schölzel BE, Pundziute G, van der Harst P, van Ramshorst J, Dirksen MT, Zivelonghi C, Agostoni P, van der Heyden JAS, Wykrzykowska JJ, Scholte MJ, Nef HM, Kofflard MJM, van Royen N, Alings M, Kedhi E.

Neth Heart J. 2018 Oct;26(10):473-483. doi: 10.1007/s12471-018-1143-z. Review.

9.

IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3).

van den Berg VJ, Haskard DO, Fedorowski A, Hartley A, Kardys I, Caga-Anan M, Akkerhuis KM, Oemrawsingh RM, van Geuns RJ, de Jaegere P, van Mieghem N, Regar E, Ligthart JMR, Umans VAWM, Serruys PW, Melander O, Boersma E, Khamis RY.

EBioMedicine. 2018 Oct;36:63-72. doi: 10.1016/j.ebiom.2018.08.023. Epub 2018 Aug 18.

10.

SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease.

Vroegindewey MM, Schuurman AS, Oemrawsingh RM, van Geuns RJ, Kardys I, Ligthart J, Daemen J, Boersma E, Serruys PW, Akkerhuis KM.

PLoS One. 2018 Jul 2;13(7):e0200076. doi: 10.1371/journal.pone.0200076. eCollection 2018.

11.

SYNTAX score in relation to intravascular ultrasound and near-infrared spectroscopy for the assessment of atherosclerotic burden in patients with coronary artery disease.

Vroegindewey MM, Schuurman AS, Kardys I, Anroedh SS, Oemrawsingh RM, Ligthart J, Garcia-Garcia HM, van Geuns RM, Regar E, Van Mieghem NM, Serruys PW, Boersma E, Akkerhuis M.

EuroIntervention. 2019 Jan 20;14(13):1408-1415. doi: 10.4244/EIJ-D-17-00827.

12.

Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up.

Schuurman AS, Vroegindewey M, Kardys I, Oemrawsingh RM, Cheng JM, de Boer S, Garcia-Garcia HM, van Geuns RJ, Regar ES, Daemen J, van Mieghem NM, Serruys PW, Boersma E, Akkerhuis KM.

Eur Heart J. 2018 Jan 21;39(4):295-302. doi: 10.1093/eurheartj/ehx247.

PMID:
28531282
13.

Cohort profile of BIOMArCS: the BIOMarker study to identify the Acute risk of a Coronary Syndrome-a prospective multicentre biomarker study conducted in the Netherlands.

Oemrawsingh RM, Akkerhuis KM, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Liem A, Haitsma D, van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Ilmer B, Dijkgraaf R, de Winter RJ, The SH, Wardeh AJ, Hermans W, Cramer E, van Schaik RH, Hoefer IE, Doevendans PA, Simoons ML, Boersma E.

BMJ Open. 2016 Dec 23;6(12):e012929. doi: 10.1136/bmjopen-2016-012929.

14.

Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography.

Buljubasic N, Akkerhuis KM, Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, de Boer SP, Regar E, van Geuns RM, Serruys PW, Boersma E, Kardys I.

Coron Artery Dis. 2017 Jan;28(1):23-32.

15.

Plasma cystatin C and neutrophil gelatinase-associated lipocalin in relation to coronary atherosclerosis on intravascular ultrasound and cardiovascular outcome: Impact of kidney function (ATHEROREMO-IVUS study).

Brankovic M, Akkerhuis KM, Buljubasic N, Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Regar E, Serruys PW, van Geuns RJ, Boersma E, Kardys I.

Atherosclerosis. 2016 Nov;254:20-27. doi: 10.1016/j.atherosclerosis.2016.09.016. Epub 2016 Sep 17.

16.

Integrated Biomarker and Imaging Study 3 (IBIS-3) to assess the ability of rosuvastatin to decrease necrotic core in coronary arteries.

Oemrawsingh RM, Garcia-Garcia HM, van Geuns RJ, Lenzen MJ, Simsek C, de Boer SP, Van Mieghem NM, Regar E, de Jaegere PP, Akkerhuis KM, Ligthart JM, Zijlstra F, Serruys PW, Boersma E.

EuroIntervention. 2016 Aug 20;12(6):734-9. doi: 10.4244/EIJV12I6A118.

17.

Haptoglobin polymorphism in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and near-infrared spectroscopy in patients with coronary artery disease.

Buljubasic N, Oemrawsingh RM, Smeets MB, Cheng JM, Regar E, van Geuns RJ, Serruys PW, Boersma E, Akkerhuis KM, Kardys I, Arslan F.

Int J Cardiol. 2016 Oct 15;221:682-7. doi: 10.1016/j.ijcard.2016.07.126. Epub 2016 Jul 9.

PMID:
27423090
18.

Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.

Oemrawsingh RM, Akkerhuis KM, Van Vark LC, Redekop WK, Rudez G, Remme WJ, Bertrand ME, Fox KM, Ferrari R, Danser AH, de Maat M, Simoons ML, Brugts JJ, Boersma E; PERGENE investigators.

J Am Heart Assoc. 2016 Mar 28;5(3):e002688. doi: 10.1161/JAHA.115.002688.

19.

PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.

Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Boersma E, van Geuns RJ, Serruys PW, Kardys I, Akkerhuis KM.

Atherosclerosis. 2016 May;248:117-22. doi: 10.1016/j.atherosclerosis.2016.03.010. Epub 2016 Mar 11.

PMID:
27015246
20.

High-sensitivity Troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study.

Oemrawsingh RM, Cheng JM, García-García HM, Kardys I, van Schaik RH, Regar E, van Geuns RJ, Serruys PW, Boersma E, Akkerhuis KM.

Atherosclerosis. 2016 Apr;247:135-41. doi: 10.1016/j.atherosclerosis.2016.02.012. Epub 2016 Feb 15.

21.

Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study.

Cheng JM, Suoniemi M, Kardys I, Vihervaara T, de Boer SP, Akkerhuis KM, Sysi-Aho M, Ekroos K, Garcia-Garcia HM, Oemrawsingh RM, Regar E, Koenig W, Serruys PW, van Geuns RJ, Boersma E, Laaksonen R.

Atherosclerosis. 2015 Dec;243(2):560-6. doi: 10.1016/j.atherosclerosis.2015.10.022. Epub 2015 Oct 23.

PMID:
26523994
22.

Smoking in Relation to Coronary Atherosclerotic Plaque Burden, Volume and Composition on Intravascular Ultrasound.

Buljubasic N, Akkerhuis KM, de Boer SP, Cheng JM, Garcia-Garcia HM, Lenzen MJ, Oemrawsingh RM, Battes LC, Rijndertse M, Regar E, Serruys PW, van Geuns RJ, Boersma E, Kardys I.

PLoS One. 2015 Oct 22;10(10):e0141093. doi: 10.1371/journal.pone.0141093. eCollection 2015.

23.

Release of growth-differentiation factor 15 and associations with cardiac function in adult patients with congenital heart disease.

Eindhoven JA, van den Bosch AE, Oemrawsingh RM, Baggen VJ, Kardys I, Cuypers JA, Witsenburg M, van Schaik RH, Roos-Hesselink JW, Boersma E.

Int J Cardiol. 2016 Jan 1;202:246-51. doi: 10.1016/j.ijcard.2015.09.010. Epub 2015 Sep 14.

PMID:
26402453
24.

High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention.

Oemrawsingh RM, Cheng JM, Akkerhuis KM, Kardys I, Degertekin M, van Geuns RJ, Daemen J, Boersma E, Serruys PW, van Domburg RT.

EuroIntervention. 2016 Jun 20;12(3):345-51. doi: 10.4244/EIJY15M07_04.

25.

Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA.

van der Leeuw J, Oemrawsingh RM, van der Graaf Y, Brugts JJ, Deckers JW, Bertrand M, Fox K, Ferrari R, Remme WJ, Simoons ML, Boersma E, Visseren FL.

Int J Cardiol. 2015 Mar 1;182:194-9. doi: 10.1016/j.ijcard.2014.12.046. Epub 2014 Dec 23.

26.

Near-infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease.

Oemrawsingh RM, Cheng JM, García-García HM, van Geuns RJ, de Boer SP, Simsek C, Kardys I, Lenzen MJ, van Domburg RT, Regar E, Serruys PW, Akkerhuis KM, Boersma E; ATHEROREMO-NIRS Investigators.

J Am Coll Cardiol. 2014 Dec 16;64(23):2510-8. doi: 10.1016/j.jacc.2014.07.998.

27.

Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Results of the ATHEROREMO-IVUS study.

Sonneveld MA, Cheng JM, Oemrawsingh RM, de Maat MP, Kardys I, Garcia-Garcia HM, van Geuns RJ, Regar E, Serruys PW, Boersma E, Akkerhuis KM, Leebeek FW.

Thromb Haemost. 2015 Mar;113(3):577-84. doi: 10.1160/TH14-07-0589. Epub 2014 Dec 4.

PMID:
25472874
28.

Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: results from the ATHEROREMO-IVUS study.

Battes LC, Akkerhuis KM, Cheng JM, Garcia-Garcia HM, Oemrawsingh RM, de Boer SP, Regar E, van Geuns RJ, Serruys PW, Boersma E, Kardys I.

Int J Cardiol. 2014 Dec 20;177(3):847-53. doi: 10.1016/j.ijcard.2014.11.001. Epub 2014 Nov 4.

PMID:
25465831
29.

Relation of C-reactive protein to coronary plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovascular outcome in patients with acute coronary syndrome or stable angina pectoris (from the ATHEROREMO-IVUS study).

Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Akkerhuis KM, Kardys I, de Boer SP, Langstraat JS, Regar E, van Geuns RJ, Serruys PW, Boersma E.

Am J Cardiol. 2014 Nov 15;114(10):1497-503. doi: 10.1016/j.amjcard.2014.08.013. Epub 2014 Aug 27.

PMID:
25248815
30.

Circulating chemokines in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and cardiovascular outcome.

Cheng JM, Oemrawsingh RM, Akkerhuis KM, Garcia-Garcia HM, de Boer SP, Battes LC, Buljubasic N, Lenzen MJ, de Jaegere PP, van Geuns RJ, Serruys PW, Kardys I, Boersma E.

Biomarkers. 2014 Nov;19(7):611-9. doi: 10.3109/1354750X.2014.957725. Epub 2014 Sep 8.

PMID:
25196123
31.

Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: results from the ATHEROREMO-IVUS study.

Battes LC, Cheng JM, Oemrawsingh RM, Boersma E, Garcia-Garcia HM, de Boer SP, Buljubasic N, Mieghem NA, Regar E, Geuns RJ, Serruys PW, Akkerhuis KM, Kardys I.

Atherosclerosis. 2014 Sep;236(1):18-24. doi: 10.1016/j.atherosclerosis.2014.06.010. Epub 2014 Jun 26.

PMID:
25003948
32.

Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography.

Cheng JM, Akkerhuis KM, Meilhac O, Oemrawsingh RM, Garcia-Garcia HM, van Geuns RJ, Piquer D, Merle D, du Paty E, Galéa P, Jaisser F, Rossignol P, Serruys PW, Boersma E, Fareh J, Kardys I.

Arterioscler Thromb Vasc Biol. 2014 May;34(5):1078-84. doi: 10.1161/ATVBAHA.114.303486. Epub 2014 Mar 20.

PMID:
24651681
33.

In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study.

Cheng JM, Garcia-Garcia HM, de Boer SP, Kardys I, Heo JH, Akkerhuis KM, Oemrawsingh RM, van Domburg RT, Ligthart J, Witberg KT, Regar E, Serruys PW, van Geuns RJ, Boersma E.

Eur Heart J. 2014 Mar;35(10):639-47. doi: 10.1093/eurheartj/eht484. Epub 2013 Nov 19.

PMID:
24255128
34.

Trial participation as a determinant of clinical outcome: differences between trial-participants and Every Day Clinical Care patients in the field of interventional cardiology.

de Boer SP, van Leeuwen MA, Cheng JM, Oemrawsingh RM, van Geuns RJ, Serruys PW, Boersma E, Lenzen MJ.

Int J Cardiol. 2013 Nov 15;169(4):305-10. doi: 10.1016/j.ijcard.2013.09.011. Epub 2013 Oct 5.

PMID:
24144926
35.

Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROREMO-IVUS study.

de Boer SP, Cheng JM, Garcia-Garcia HM, Oemrawsingh RM, van Geuns RJ, Regar E, Zijlstra F, Laaksonen R, Halperin E, Kleber ME, Koenig W, Boersma E, Serruys PW.

EuroIntervention. 2014 Dec;10(8):953-60. doi: 10.4244/EIJY13M08_01.

36.

Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial.

de Mulder M, Umans VA, Cornel JH, van der Zant FM, Stam F, Oemrawsingh RM, Akkerhuis KM, Boersma E.

JAMA Intern Med. 2013 Nov 11;173(20):1896-904. doi: 10.1001/jamainternmed.2013.10074.

PMID:
24018647
37.

Health-related quality of life in the elderly three years after percutaneous coronary intervention.

Panasewicz A, Pedersen SS, Veenhuis SJ, Oemrawsingh RM, van der Giessen WJ, van Geuns RJ, Regar E, de Jaegere PP, Serruys PW, van Domburg RT.

EuroIntervention. 2013 Jul;9(3):373-81. doi: 10.4244/EIJV9I3A60.

38.

Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes.

García-García HM, Oemrawsingh RM, Brugaletta S, Vranckx P, Shannon J, Davies R, Boersma E, Serruys PW.

Atherosclerosis. 2012 Nov;225(1):142-7. doi: 10.1016/j.atherosclerosis.2012.06.064. Epub 2012 Aug 5.

PMID:
22963982
39.

Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study.

Eindhoven JA, Onuma Y, Oemrawsingh RM, Daemen J, van Nierop JW, de Jaegere PP, Boersma E, Serruys PW, van Domburg RT.

EuroIntervention. 2012 Apr;7(12):1420-7. doi: 10.4244/EIJV7I12A222.

40.

Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention.

Kardys I, Oemrawsingh RM, Kay IP, Jones GT, McCormick SP, Daemen J, Van Geuns RJ, Boersma E, Van Domburg RT, Serruys PW.

Clin Cardiol. 2012 Aug;35(8):482-9. doi: 10.1002/clc.21988. Epub 2012 Apr 9.

41.

Primary PCI during off-hours is not related to increased mortality.

de Boer SP, Oemrawsingh RM, Lenzen MJ, van Mieghem NM, Schultz C, Akkerhuis KM, van Leeuwen MA, Zijlstra F, van Domburg RT, Serruys PW, Boersma E.

Eur Heart J Acute Cardiovasc Care. 2012 Apr;1(1):33-9. doi: 10.1177/2048872612441581.

42.

The influence of optimal medical treatment on the 'obesity paradox', body mass index and long-term mortality in patients treated with percutaneous coronary intervention: a prospective cohort study.

Schenkeveld L, Magro M, Oemrawsingh RM, Lenzen M, de Jaegere P, van Geuns RJ, Serruys PW, van Domburg RT.

BMJ Open. 2012 Feb 9;2:e000535. doi: 10.1136/bmjopen-2011-000535. Print 2012.

43.

Beta blocker therapy is associated with reduced depressive symptoms 12 months post percutaneous coronary intervention.

Battes LC, Pedersen SS, Oemrawsingh RM, van Geuns RJ, Al Amri I, Regar E, de Jaegere PP, Serruys P, van Domburg RT.

J Affect Disord. 2012 Feb;136(3):751-7. doi: 10.1016/j.jad.2011.09.047. Epub 2011 Oct 26.

44.

Comparison of diagnostic criteria to detect undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome.

de Mulder M, Oemrawsingh RM, Stam F, Boersma E, Umans VA.

Heart. 2012 Jan;98(1):37-41. doi: 10.1136/heartjnl-2011-300163. Epub 2011 Jun 27.

PMID:
21708819
45.

Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants.

de Boer SP, Lenzen MJ, Oemrawsingh RM, Simsek C, Duckers HJ, van der Giessen WJ, Serruys PW, Boersma E.

Eur Heart J. 2011 Sep;32(17):2161-7. doi: 10.1093/eurheartj/ehr126. Epub 2011 May 12.

PMID:
21565848
46.

Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome.

Oemrawsingh RM, Lenderink T, Akkerhuis KM, Heeschen C, Baldus S, Fichtlscherer S, Hamm CW, Simoons ML, Boersma E; CAPTURE investigators.

Heart. 2011 Jul;97(13):1061-6. doi: 10.1136/hrt.2010.197392. Epub 2011 May 10.

PMID:
21558475
47.

Intensive management of hyperglycaemia in acute coronary syndromes. Study design and rationale of the BIOMArCS 2 glucose trial.

de Mulder M, Umans VA, Stam F, Cornel JH, Oemrawsingh RM, Boersma E.

Diabet Med. 2011 Oct;28(10):1168-75. doi: 10.1111/j.1464-5491.2011.03307.x.

PMID:
21480974
48.

Current management of hyperglycemia in acute coronary syndromes: a national Dutch survey.

de Mulder M, Oemrawsingh RM, Stam F, Boersma E, Umans VA.

Crit Pathw Cardiol. 2009 Jun;8(2):66-70; quiz 71. doi: 10.1097/HPC.0b013e3181a27fcf.

PMID:
19491572
49.

Tailor-made therapy for the prevention of acute coronary syndromes: future role of biomarkers in risk stratification and disease management.

Oemrawsingh RM, Akkerhuis KM, Boersma E.

Expert Rev Cardiovasc Ther. 2008 Apr;6(4):435-7. doi: 10.1586/14779072.6.4.435. No abstract available.

PMID:
18402533

Supplemental Content

Loading ...
Support Center